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Introduction. In recent years, nanomedicines have raised as a powerful tool to 
improve prevention, diagnosis and treatment of different pathologies. Among the 
most well investigated biomaterials, D-α-tocopheryl polyethylene glycol succinate 
(also known as TPGS) has been on the spot for the last decade. We therefore 
designed a method to biologically characterize TPGS-based nanomicelles by 
labeling them with 99mTc. Methods. Labeling process was performed by a direct 
method. The average hydrodynamic diameter of TPGS nanomicelles was 
measured by dynamic light scattering and radiochemical purity was assessed by 
thin layer chromatography. Imaging: a dynamic study was performed during the 
first hour post radioactive micelles administration in a gamma camera (TcO4
- was 
also administered for comparative purposes). Then two static images were 
acquired in ventral position: 1 hour and 12 hours post injection. Blood 
pharmacokinetics of 99mTc-TPGS during 24 h was performed. Results. Images 
revealed whole body biodistribution at a early and delayed time and 
















6.1±0.5; 3.9±0.1, Bone 1.2±0.2; 1±0.1, Heart 1.5±0.6; 0.7±0.3, Kidneys 16.6±1.3; 
26.5±1.7, Liver 8.6±1.1; 11.1±0.1 for 1 and 12 hs post injection respectively). 
Conclusion. This work demonstrated that TPGS based nanomicelles are 
susceptible to be radiolabeled with 99mTc thus they can be used to perform imaging 
studies in animal models. Moreover radiolabeling of these delivery nano systems 

















In recent years, nanomedicines have raised as a powerful tool to improve 
prevention, diagnosis and treatment of different pathologies. Their nano-sized 
range along with their high surface-to-volume ratio and their favorable physico-
chemical characteristics makes them suitable for modulation of the 
pharmacokinetic and pharmacodynamic drug profiles. In this context 
nanotechnology offers a variety of strategies to develop novel drug delivery 
systems with not only an improved drug aqueous solubility and chemical stability, 
but also with controlled drug release and preferential accumulation in certain 
tissues or in solid tumors (passive or active targeting) [1, 2]. 
Among the most well investigated biomaterials, D-α-tocopheryl polyethylene glycol 
succinate (also known as TPGS) has been on the spot for the last decade. It is the 
water-soluble form of vitamin E, resulting from the esterification of vitamin E 
succinate with polyethylene glycol 1000. It exhibits an average molecular weight of 
1,513 Da and a hydrophile-lipophile balance value of 13.2 (amphiphilic nature). 
TPGS is a Generally Regarded As Safe (GRAS)-listed oral supplement which has 
been approved by the FDA as a safe pharmaceutical adjuvant used in drug 
formulation [3]. 
Due to TPGS properties as an absorption/permeation enhancer, emulsifier, 
solubilizer and stabilizer agent, it has been investigated for the development of a 
wide variety of drug delivery systems including micelles, TPGS-based 
nanoparticles (NPs), liposomes, nanosuspensions, solid dispersions and TPGS-
based pro-drugs. For instance, TPGS-based block copolymers NPs have been 
















have been employed for paclitaxel delivery [5]. Due to TPGS amphiphilic nature, it 
has been explored as a micelle-forming biomaterial, especially for oral and 
parenteral administration in antineoplastic therapy [6-10]. In this context, it has 
been reported that TPGS could serve as a pharmaceutical additive for overcoming 
multidrug resistance and as an inhibitor of P-glycoprotein for increasing the 
cytotoxicity and bioavailability of anticancer drugs [5, 11, 12]. It has also been 
investigated for the treatment of other pathologies including the drug delivery of 
antiretrovirals and calcium channel blockers [13, 14]. 
Other properties explored for TPGS are: i) its ability to act as an adjuvant in 
vaccine systems for intranasal administration [15] and ii) its use as a nutrition 
supplement [16]. 
Recently, a new generation of multifunctional nanocarriers for simultaneous 
diagnosis and therapy, known as “theranostics” nanoformulations, has risen 
representing a new platform for personalized nanomedicines. These 
nanoformulations allow the assessment of drugs biodistribution and accumulation 
in a certain target along with the possibility of reaching therapeutic efficacy [17, 18]. 
Labeling TPGS or any of the TPGS-based nanostructures stands as a real 
challenge and the first rational step towards building a true theranostic agent. This 
first step is evaluated in this work and further research is needed to test loading 
(with a therapeutic drug) and labeling of TPGS-based nanostructures altogether. In 
addition, small animal imaging represents a powerful tool to follow up labeled 
probes and could help with characterization of nano-systems as it can show in vivo 
kinetics and organ biodistribution [19, 20]. These techniques can also provide 
















designed a method to biologically characterize TPGS-based nanomicelles by 
labeling them with 99mTc, a widely known and used radionuclide with diagnostic 
purposes in Nuclear Medicine [21]. Radiolabeling TPGS-based nanomicelles has 
an enormous potential for multiple purposes: first it can easily enlighten the 
pharmacokinetic and pharmacodynamic of this nanosystem by using noninvasive 
techniques, second it could also constitute a tumor diagnostic agent for Nuclear 
Medicine and finally and even more significant it could, potentially and with further 
research needed, constitute itself a theranostic agent if it is susceptible to carry a 
therapeutic drug and to stay labeled.  
 
Materials and Methods 
Micelles preparation 
For the TPGS nanomicelles preparation, 10 g of commercial TPGS was weighted 
and dissolved in 100 mL of distilled water with continuous agitation and 
temperature (30°C) until a homogeneous dispersion was achieved. Then samples 
were equilibrated for 24 h and filtered by clarifying filters (0.2 µm, cellulose nitrate) 
before use. Finally, the suspension was used to perform the radiolabeling 
procedure. 
 
Micellar size distribution and morphology 
The average hydrodynamic diameter (Dh) of TPGS nanomicelles (10% w/v) was 
measured by dynamic light scattering (DLS, scattering angle of ɵ = 173° to the 
incident beam, Zetasizer Nano-Zs, Malvern Instruments, United Kingdom) at 25 °C. 
















The morphology of the TPGS nanomicelles (10% w/v) was characterized by 
transmission electron microscopy (TEM, Philips CM-12 TEM apparatus, FEI 
Company, The Netherlands). Briefly, aliquots were placed onto a grid and covered 
with Fomvar film, stained with 5 μL of phosphotungstic acid solution (1% w/v), 
washed with distilled water (5 μL) and dried into a silicagel container. 
 
Radiolabeling 
Labeling process was performed by a direct method as follows: a 10% w/v TPGS 
dispersion was incubated for 2 h with 25 mCi of 99mTcO4- eluted from a 99Mo-99mTc 
generator (Laboratorios BACON, Argentina). SnCl2 (Sigma-Aldrich, USA) was 
dissolved using HCl 6 N (Anedra, Argentina) and then added to the reaction vial 
reaching a concentration of 2.5 mg/mL. The radiolabeling was assessed prior to 
99mTc-TPGS based nanomicelles intravenous administration by using paper 
chromatography: Whatman N°1 (W&R BALSTON Ltd, England) paper and methyl-
ethyl-cetone (Cicarelli, Argentina) as stationary and mobile phases respectively.  
 
Serum Stability 
Serum samples (3 h post injection) were assessed by paper chromatography: 
Whatman N°1 (W&R BALSTON Ltd, England) paper and methyl-ethyl-cetone 


















All animal procedures were approved by the Ethical Committee for the Use and 
Care Laboratory Animals (CICUAL) of the School of Pharmacy and Biochemistry, 
Universidad de Buenos Aires (Res CD 3761/13). 
Sprague Dawley rats (250-300 g) were kept in stainless steel cages under a 12 h 
light 12 h darkness cycle. Food and water were available ad libitum. Animals were 
anesthetized using ketamine-xilazine (90 mg/Kg-5 mg/Kg) [22] and placed ventrally 
over the collimator for the administration of 74 MBq of radioactive micelles (N=3) or 
free radiolabel (N=3) through the tail vein (intravenously). Pressure was applied 
until hemostasis was achieved. After dynamic imaging and 1 h static acquisition, 
animals were kept in the same conditions but in a specially adapted bunker until 
the 12 h image. 
 
Imaging and Pharmacokinetics 
Small animal imaging was performed using a small field of view gamma camera 
(OHIONUCLEAR, Software; IM512P, ALFANUCLEAR, Argentina) equipped with a 
high resolution parallel hole collimator. A dynamic study was performed during the 
first hour post radioactive micelles administration. Then two static images were 
acquired in ventral position: 1 hour and 12 h post injection. Dynamic study: 1 
frame/second (for 60 seconds) and then 1 frame/3 min (60 minutes); 256x256 
matrix, 1.5 zoom. Static studies: 256x256 matrix; 1.5 zoom; more than 1.5 million 
counts (20-35 min scan). To analyze the results regions of interest (ROIs) were 
created on relevant organs in order to get semi quantitative results of the 
radioactive micelles biodistribution and they were expressed as % Total counts 
















In order to correlate the imaging results with pharmacokinetics of 99mTc-TPGS 
based nanomicelles serum samples were taken (100 uL) at different time points 
post injection (10 min, 40 min, 1 h, 2 h, 3 h, 6 h, 12 h and 24 h) and radioactivity 
concentration was measured in a solid scintillation counter. Appropriate standards 
were built in order to express the results as %Injected dose. 
 
Results 
The spherical morphology and size of TPGS-based nanomicelles is shown in 
Figure 1. The difference on micellar size between both techniques could be 
attributed to the micellar concentration used in this study. For the microscopy 
assay samples were dried, therefore, micellar aggregates could be expected since 
micelles are considered “dynamic systems” where their dilution can modify their 
hydrodynamic diameter and morphology [23, 24]. Paper chromatography results 
revealed 95±5 % of the radioactivity at the strip origin, showing the success of the 
radiolabeling method given that the predictable impurities remain below the 
commonly accepted limits for this kind of probes [25]. The results of the in vivo 
stability in serum samples (98±1 %) were in harmony with some of the imaging 
results which show that radiochemical purity assay was suitable for this purpose. 
Figure 2 shows the in vivo localization of TPGS-based nanomicelles at 1 hour post 
administration. Nanomicelles essentially reached heart, liver, kidneys, bone and 
bladder by the first hour of biodistribution. This constitutes evidence of the 
accumulation of the micelles in organs which have cells from reticuloendothelial 
system (bone marrow and liver) but it also shows a possible elimination of the renal 
















biodistribution after 12 hours of administration, kidneys and liver increased their 
TPGS nanomicelles content whereas heart decreased it. A small abdominal uptake 
can be noticed probably due to intestinal content. Further metabolic studies should 
be performed in order to characterize elimination pathways and their kinetics in 
between the time points evaluated here and even longer ones.  
Intravenous administration is a key factor when analyzing pharmacokinetics of a 
new nano-system. In this case, TPGS based nanomicelles were radiolabeled with 
99mTc which allowed follow up of the biodistribution of the 99mTc-TPGS since its 
administration. Figure 4 and 5 show the first seconds of the intravenous 
administration of radiolabelled nanomicelles and the free radiolabel (99mTcO4
-) as a 
control. It is noticeable the moment in which the radiopharmaceutical and the free 
label reach the heart (few seconds post injection) and from this moment on they 
began to distribute throughout the whole body. This is the perfusion phase which 
lasted for 1 minute (only the first seconds are shown). 
Figure 6 and 7 show functional phases of 99mTc-TPGS and 99mTcO4- respectively. 
The upper panel (from 1.5 to 7 min) shows early biodistribution and the lower, the 
later one (from 47.5 to 53 min). There are clear and very noticeable differences 
among 99mTc-TPGS and the free label in their biodistribution and pharmacokinetics 
at the early and the latter stages. It is worth mentioning the high 99mTcO4- uptake in 
stomach and mouth. However, these two sites do not appear in 99mTc-TPGS 
images, proving the labelling of the nanomicelles and the absence of free 
radiolabel. As mentioned above, those results were predicted accurately with 
radiochemical purity assay. On the light of that result it can be concluded that the 
















demonstrated by serum stability assay), at least until specific tissues were 
reached. Table 1 shows semi quantitative analysis of the organs of interest. At 12 
hours post injection the activity accumulated in kidneys and liver was about 40% 
higher than at the first hour meaning that micelles continued accumulating in both 
organs in a time dependent way. Bone uptake was evaluated by placing the 
regions of interest (ROIs) over the knees which rendered similar values at both 
time points. An interesting fact is that soft tissue as well as cardiac tissue had 
almost 50% less activity at the delayed image when compared to the early one. 
This could reflect that at the first hour micelles were still in circulation and 12 hours 
later most of them were already localized in specific tissues. An extended 
circulating time is expected for these PEG exposing nanomicelles [26]. Moreover a 
two phase decay curve was fitted in 99mTc-TPGS serum concentration over time as 
it can be seen in Figure 8. This means that clearance from blood has different 
constant rates during early time points when compared to delayed time points after 
administration. This shows that static images taken at 1 and 12 h were 
representative of both phases. 
 
Discussion 
It is worth mentioning the fact that placing ROIs in planar images can lead to 
structure superposition which is an inherent characteristic of the semiquantification 
performed using this technique. Some regions are more critical than others, 
nevertheless biological distribution results can be obtained with all the advantages 
















The application of this imaging technique allows performing the biological 
characterization of TPGS nanomicelles, being these data useful to predict their 
application on different pathologies, as a potential diagnostic tool and a drug 
delivery system for passive or active targeting in infectious reservoirs (theranostic 
agent). Among the different infectious diseases which present anatomical 
reservoirs, extrapulmonary tuberculosis (epTB) (affecting 50% of human 
immunodeficiency virus (HIV)-positive patients) exhibits a skeletal/articular form 
(35% of epTB cases) which involves arthritis and extraspinal osteomyelitis. Also it 
has been described renal tuberculosis, being the kidneys the most affected organs 
and tuberculous pericarditis [27, 28]. In case of HIV antiretroviral therapy, the 
overcoming of latent HIV reservoirs throughout the body involves one of the main 
objectives of the present Highly Active Antiretroviral Therapy (HAART). Indeed, the 
gut- and rectal associated lymphoid tissue as well as the intestinal macrophages 
have been described as viral reservoirs for HIV type 1 [29]. Among the parasite 
diseases, malaria caused by Plasmodium vivax (a worldwide severe malaria form) 
also is being on the spot in past years due to the description of infection relapse by 
liver hypnozoites activation. In this framework, liver accumulation of TPGS micelles 
could enhance the current therapy towards malaria elimination [30]. 
Thereby this radiopharmaceutical approach provides biological behavior 
understanding of the nanomicelles in a way no other technique does. Radionuclide 
based imaging contributes, in this way, to preclinical phases of new drugs or 
delivery systems development. The information provided and the clinical traslation 
of this imaging technique is not comparable to any other practice. The key lays on 
















help elucidate the true potentialities of this nanosystem avoiding theoretical 
speculations. In addition, research in this area raises awareness of the possible 
side effects of its administration. Serum concentration studies allow us to 
understand pharmacokinetics of this radiolabelled probe and to validate the 
imaging time points chosen. Therefore we consider them complementary studies to 
imaging assessment. 
This work demonstrated that TPGS based nanomicelles are susceptible to be 
radiolabelled with 99mTc, thus they can be used to perform imaging studies in 
animal models. Interestingly, these novel nanosystems could be successfully 
employed as a potential diagnostic agent. Furthermore, commercially available 
FDA approved-biomaterials could offer the possibility of develop cost-viable and 
scalable products without the requirement of long-term/expensive biocompatibility 
assays. This issue stands as extremely useful for the potential bench-to-bed 
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 %Total counts 
 Soft 
Tissue 
Bone Heart Kidneys Liver Background 
1 h 
PI 
6.1±0.5 1.2±0.2 1.5±0.6 16.6±1.3 8.6±1.1 0.15±0.01 
12 h 
PI 
3.9±0.1 1.0±0.1 0.7±0.3 26.5±1.7 11.1±0.1 0.080±0.002 
 
Table 1. Semiquantification of the %Total for specific organs. Results were 
calculated by creating ROIs. Two different time points are presented: 1 and 12 

















Figure 1. Size distribution (a) and TEM micrographs (b) of TPGS nanomicelles 
(10% w/v), scale bar: 100 nm. (c) Macroscopic aspect of a TPGS micellar 
dispersion in distilled water. 
 
Figure 2. Biodistribution of 99mTc radiolabelled TPGS-based nanomicelles (74 
MBq). Static image was acquired 1 hour post administration in ventral view (256 x 
256 matrix, 1.5 zoom, ≥1.5 million counts, 20 min scan). Anesthesia: 
ketamine/xilazine. Color Band scale is shown. 
 
Figure 3. Biodistribution of 99mTc radiolabelled TPGS-based nanomicelles (74 
MBq). Static image was acquired 12 hours post administration in ventral view (256 
x 256 matrix, 1.5 zoom, ≥1.5 million counts, 35 min scan). Anesthesia: 
ketamine/xilazine. Color Band scale is shown. 
 
Figure 4. Perfusion Phase of the dynamic study of 99mTc-TPGS. The study began 
with the radiopharmaceutical intravenous administration. Acquisitions were made 
as 1 second /frame (256 x 256 matrix, 1.5 zoom, 60 seconds). Numbers below 
each frame represent the seconds post injection. Anesthesia: ketamine/xilazine. 
Standard scale is shown. 
 
Figure 5. Perfusion Phase of the dynamic study of 99mTcO4
-. The study began with 
the free label administration. Acquisitions were made as 1 frame/second (256 x 
256 matrix, 1.5 zoom, 60 seconds). Numbers below each frame represent the 

















Figure 6. Functional Phase of the dynamic study of 99mTc-TPGS (37 MBq). The 
study began 1 minute post radiopharmaceutical intravenous administration. 
Acquisitions were made as 30 seconds/frame (256 x 256 matrix, 1.5 zoom, 60 
minutes). Numbers below each frame represent the minutes post injection. 
Anesthesia: ketamine/xilazine. Standard scale is shown. 
 
Figure 7. Functional Phase of the dynamic study of 99mTcO4
- (37 MBq). The study 
began 1 minute post radiopharmaceutical intravenous administration. Acquisitions 
were made as 30 seconds/frame (256 x 256 matrix, 1.5 zoom, 60 minutes). 
Numbers below each frame represent the minutes post injection. Anesthesia: 
ketamine/xilazine. Yellow scale is shown. 
 
Figure 8. Pharmacokinetics of 99mTc-TPGS based nanomicelles. 99mTc-TPGS was 
injected (350 µCi) intravenously by the tail vein. Serum concentration (100 µL 
sample) was expressed as a % Injected dose (%ID) and it is plotted as media±SD 
(N=3; error bars that cannot be seen are smaller than dots). A non linear curve 
(two phase decay) was fitted and parameters are shown: constant rates for fast 
and slow phases (Kfast, Kslow respectively); extrapolated %Injected dose at 0 h 
(%ID0); Plateau: %ID value at theoretical infinite times (Pl). 
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Fig. 2 
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Fig. 3 
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Fig. 5 
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Fig. 7 
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Fig. 8 
